Thrombolysis with saruplase versus streptokinase in acute myocardial infarction: Five-year results of the primi trial

American Heart Journal

Volumn 138, Issue 3 I, 1999, Pages 518-524

  Spiecker, M ^a   Windeler, J ^a   Vermeer, F ^a   Michels, R ^a   Seabra Gomes, R ^a   Vom Dahl, J ^a   Kerber, S ^a   Verheugt, F W A ^a   Westerhof, P W ^a   Bar, F W ^a   Nixdorff, U ^a   Barth, H ^a   Hopkins, G R ^a   Von Fisenne, M J M ^a   Meyer, J ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SARUPLASE; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD CLOT LYSIS; CORONARY ARTERY BYPASS GRAFT; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART FAILURE; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; STROKE; SURVIVAL RATE;

EID: 0032841636     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70155-9     Document Type: Article

References (25)

1. Lenderink T, Simoons ML, Van Es GA, et al. Benefit of thrombolytic therapy is sustained throughout 5 years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge: the European Cooperative Study Group. Circulation 1995;92:1110-6.
2. ISIS-2. Four-year mortality follow-up of 17,187 patients after fibrinolytic and antiplatelet therapy in suspected acute myocardial infarction. Circulation 1993;88(suppl II):II-291.
3. Simoons ML, Vos J, Tijssen JG, et al. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of The Netherlands. J Am Coll Cardiol 1989;14:1609-15.
4. Cerqueira MD, Maynard C, Richtie JL, et al. Long-term survival in 618 patients from the Western Washington Streptokinase in Myocardial Infarction trials. J Am Coll Cardiol 1992;20:1452-9.
5. Bär FW, Meyer J, Vermeer F, et al. Early patency and reocclusion: comparison of saruplase and alteplase in acute myocardial infarction: from the SESAM study. Am J Cardiol 1997;79:727-32.
6. PRIMI Trial Study Group. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989;1:863-8.
7. Diefenbach C, on behalf of the PRIMI Study Group. One-year follow-up in a randomized double-blind trial of saruplase versus streptokinase in acute myocardial infarction: long-term results of the PRIMI trial. Coron Artery Dis 1992;3:925-31.
8. Brouwer MA, Böhncke JR, Veen G, et al. Adverse long-term effects of reocclusion after coronary thrombolysis. J Am Coll Cardiol 1995; 26:1440-4.
9. Mueller HS, Forman SA, Menegus MA, et al. Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial: the TIMI Investigators. J Am Coll Cardiol 1995;26:900-7.
10. White HD, Cross DB, Elliott JM, et al. Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation 1994;89:61-7.
11. Newby LK, Rutsch WR, Califf RM, et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy: GUSTO-1 Investigators. J Am Coll Cardiol 1996;27:1646-55.
12. Nixdorff U, Erbel R, Pop T, et al. Long-term follow-up of global and regional left ventricular function by 2-dimensional echocardiography after thrombolytic therapy in acute myocardial infarction. Int J Cardiol 1993;41:31-47.
13. Picard MH, Wilkins GT, Ray P, et al. Long-term effects of acute thrombolytic therapy on ventricular size and function. Am Heart J 1993;126:1-10.
14. Tebbe U, Windeler J, Boesl I, et al, on behalf of the LIMITS Study Group. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS Study). J Am Coll Cardiol 1995;26:365-73.
15. de Vreede JJM, Gorgels APM, Verstaaten GMP, et al. Did prognosis after acute myocardial infarction change during the past 30 years? A meta-analysis. J Am Coll Cardiol 1991;18:698-706.
16. Torp-Pedersen C, Hildebrandt P, Köber L, et al. Improving long-term survival of patients with acute myocardial infarction from 1977-1988 in a region of Denmark. Eur Heart J 1995;16:14-20.
17. Stevenson R, Ranjadayalan K, Wilkinson P, et al. Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. Br Med J 1993;307:349-53.
18. Grijseels EW, Bouten MJ, Lenderink T, et al. Pre-hospital thrombolytic therapy with either alteplase or streptokinase: practical applications, complications and long-term results in 529 patients. Eur Heart J 1995;12:1833-8.
19. Brouwer MA, Martin JS, Maynard C, et al. Influence of early prehospital thrombolysis on mortality and event-free survival (the Myocardial Infarction Triage and Intervention [MITI] Randomized Trial): MITI Project Investigators. Am J Cardiol 1996;78:497-502.
20. Gruppo Italiano per lo Studio della Streptochinasi nell Infarto Miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 1987;2:871-4.
21. Bounous EP, Mark DB, Pollock BG, et al. Surgical survival benefits for coronary disease patients with left ventricular dysfunction. Circulation 1988;78:I-151-7.
22. Moliterno DJ, Lange RA, Willard JE, et al. Surgical restoration of antegrade flow in the occluded infarct artery improves long-term survival in patients with multivessel coronary artery disease. Coron Artery Dis 1993;4:995-9.
23. O'Keefe JH Jr, Allan JJ, McCallister BD, et al. Angioplasty versus bypass surgery for multivessel coronary artery disease with left ventricular ejection fraction < or = 40%. Am J Cardiol 1993;71:897-901.
24. Spiecker M, Erbel R, Diefenbach C, et al. Long-time follow-up after myocardial infarction treated with thrombolysis and acute or elective revascularisation. Med Klin 1992;87:343-9.
25. Tebbe U, Michels R, Adgey J, et al. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS equivalence trial. J Am Coll Cardiol 1998;31:487-93.